US20060276497A1 - Novel multicyclic compounds and the use thereof - Google Patents

Novel multicyclic compounds and the use thereof Download PDF

Info

Publication number
US20060276497A1
US20060276497A1 US11/455,356 US45535606A US2006276497A1 US 20060276497 A1 US20060276497 A1 US 20060276497A1 US 45535606 A US45535606 A US 45535606A US 2006276497 A1 US2006276497 A1 US 2006276497A1
Authority
US
United States
Prior art keywords
substituted
group
substituent
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/455,356
Other languages
English (en)
Inventor
Sankar Chatterjee
James Diebold
Derek Dunn
Robert Hudkins
Reddeppareddy Dandu
Gregory Wells
Allison Zulli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/850,858 external-priority patent/US7122679B2/en
Application filed by Cephalon LLC filed Critical Cephalon LLC
Priority to US11/455,356 priority Critical patent/US20060276497A1/en
Assigned to CEPHALON, INC. reassignment CEPHALON, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHATTERJEE, SANKAR, DIEBOLD, JAMES L., DUNN, DEREK, HUDKINS, ROBERT L., ZULLI, ALLISON L., DANDU, REDDEPPAREDDY, WELLS, GREGORY J.
Publication of US20060276497A1 publication Critical patent/US20060276497A1/en
Priority to MX2008016348A priority patent/MX2008016348A/es
Priority to SI200731252T priority patent/SI2066324T1/sl
Priority to PT78096799T priority patent/PT2066324E/pt
Priority to NZ573643A priority patent/NZ573643A/en
Priority to PL07809679T priority patent/PL2066324T3/pl
Priority to DK07809679.9T priority patent/DK2066324T3/da
Priority to JP2009516545A priority patent/JP5385133B2/ja
Priority to CN200780029096.2A priority patent/CN101500563B/zh
Priority to CA2655014A priority patent/CA2655014C/en
Priority to PCT/US2007/014300 priority patent/WO2007149451A2/en
Priority to ES07809679T priority patent/ES2416309T3/es
Priority to AU2007261464A priority patent/AU2007261464B2/en
Priority to EP07809679.9A priority patent/EP2066324B1/en
Priority to IL195821A priority patent/IL195821A/en
Priority to HK09109830.6A priority patent/HK1131747A1/xx
Priority to US12/949,254 priority patent/US8716493B2/en
Priority to CY20131100589T priority patent/CY1114153T1/el
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to novel multicyclic compounds and the use thereof. More particularly, the present invention relates to novel multicyclic compounds and their use, for example, for the mediation of enzyme activity.
  • Poly(ADP-ribose) polymerase (PARP, also called poly(ADP-ribose) synthetase, or PARS) is a nuclear enzyme which catalyzes the synthesis of poly(ADP-ribose) chains from NAD + in response to single-stranded DNA breaks as part of the DNA repair process (de Murcia et al. Trends Biochem. Sci. 1994, 19,172; Alvarez-Gonzalez et al. Mol. Cell. Biochem. 1994, 138, 33.).
  • the chromatin-associated protein substrates for ADP-ribosylation which include histones, DNA metabolizing enzymes and PARP itself, are modified on surface glutamate residues.
  • PARP catalyzes attachment of one ADP-ribose unit to the protein (initiation), followed by polymerization of as many as 200 ADP-ribose monomers (elongation) via 2′-1′′ glycosidic linkages. In addition, PARP catalyzes branching of the polymer at a lower frequency.
  • the role of PARP in the DNA repair process is incompletely defined.
  • the binding of PARP to nicked double-stranded DNA is suggested to facilitate the repair process by transiently blocking DNA replication or recombination.
  • the subsequent poly(ADP-ribosyl)ation of PARP and histones may result in introduction of a substantial negative charge, causing repulsion of the modified proteins from the DNA.
  • the chromatin structure is then proposed to relax, enhancing the access of DNA repair enzymes to the site of damage.
  • levels of ATP may decrease precipitously (since synthesis of one molecule of NAD + requires four molecules of ATP) and the cell may die through depletion of its energy stores.
  • Inhibitors of PARP may also display neuroprotective efficacy in animal models of stroke.
  • the potent PARP inhibitor DPQ (3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone) (Suto et al., U.S. Pat. No. 5,177,075) provided a 54% reduction in infarct volume in a rat model of focal cerebral ischemia (permanent MCAo and 90 min bilateral occlusion of the common carotid artery) following i.p. dosing (10 mg/kg) two hours prior to and two hours after the initiation of ischemia (Takahashi et al. Brain Res. 1997, 829, 46).
  • 3-AB also enhanced functional recovery 24 hours after ischemia, attenuated the decrease in NAD + levels in ischemic tissues, and decreased the synthesis of poly(ADP-ribose) polymers as determined by immunohistochemistry.
  • mice in which the PARP gene has been rendered non-functional have also helped to validate the role of PARP in neurodegeneration.
  • Neurotoxicity due to NMDA, NO, or oxygen-glucose deprivation was virtually abolished in primary cerebral cortical cultures from PARP ⁇ / ⁇ mice (Eliasson et al. Nature Med. 1997, 3, 1089).
  • an 80% reduction in infarct volume was observed in PARP ⁇ / ⁇ mice, and a 65% reduction was noted in PARP +/ ⁇ mice.
  • PARP Activation of PARP has been implicated in the functional deficits that may result from traumatic brain injury and spinal cord injury.
  • PARP ⁇ / ⁇ mice displayed significantly improved motor and cognitive function as compared to PARP +/+ mice (Whalen et al. J. Cereb. Blood Flow Metab. 1999, 19, 835). Peroxynitrite production and PARP activation have also been demonstrated in spinal cord-injured rats (Scott et al. Ann. Neurol. 1999, 45, 120). These results suggest that inhibitors of PARP may provide protection from loss of function following head or spinal trauma.
  • PARP as a mediator of cell death following ischemia and reperfusion
  • the role of PARP as a mediator of cell death following ischemia and reperfusion may not be limited to the nervous system.
  • a recent publication reported that a variety of structurally distinct PARP inhibitors, including 3-AB and related compounds, reduce infarct size following cardiac ischemia and reperfusion in the rabbit (Thiemermann et al. Proc. Nat. Acad. Sci. 1997, 94, 679).
  • inhibition of PARP reduced infarct volume and contractile dysfunction following global ischemia and reperfusion. Skeletal muscle necrosis following ischemia and reperfusion was also attenuated by PARP inhibitors.
  • PARP inhibitor could contribute to a positive outcome following myocardial infarction.
  • a particularly useful application of a PARP inhibitor might involve administration concurrent with a treatment designed to reperfuse the affected area of the heart, including angioplasty or a clot-dissolving drug such as tPA.
  • the activity of PARP is also implicated in the cellular damage that occurs in a variety of inflammatory diseases. Activation of macrophages by pro-inflammatory stimuli may result in the production of nitric oxide and superoxide anion, which combine to generate peroxynitrite, resulting in formation of DNA single-strand breaks and activation of PARP.
  • the role of PARP as a mediator of inflammatory disease is supported by experiments employing PARP ⁇ / ⁇ mice or inhibitors of PARP in a number of animal models. For example, joints of mice subjected to collagen-induced arthritis contain nitrotyrosine, consistent with generation of peroxynitrite (Szabo et al. J. Clin. Invest. 1998, 100, 723).
  • the PARP inhibitor 5-iodo-6-amino-1,2-benzopyrone reduced the incidence and severity of arthritis in these animals, decreasing the severity of necrosis and hyperplasia of the synovium as indicated by histological examination.
  • 3-AB inhibited the histological injury, pleural exudate formation and mononuclear cell infiltration characteristic of the inflammatory process (Cuzzocrea et al. Eur. J. Pharmacology 1998, 342, 67).
  • the activation of PARP is involved in the induction of experimental diabetes initiated by the selective beta cell toxin streptozocin (SZ). Substantial breakage of DNA may be induced by SZ, resulting in the activation of PARP and depletion of the cell's energy stores as described above in Yamamoto et al.(1981). In cells derived from PARP ⁇ / ⁇ mice, exposure to reactive oxygen intermediates results in attenuated depletion of NAD + and enhanced cell viability relative to wild-type cells (Heller et al. J. Biol. Chem. 1995, 270, 11176). Similar effects were observed in wild-type cells treated with 3-AB.
  • PARP inhibitors Another potential therapeutic utility of PARP inhibitors involves enhancement of the anti-tumor activity of radiation or DNA-damaging chemotherapeutic agents (Griffin et al. Biochemie 1995, 77, 408). Since polyADP-ribosylation occurs in response to these treatments and is part of the DNA repair process, a PARP inhibitor might be expected to provide a synergistic effect.
  • protein kinases play a critical role in the control of cells.
  • kinases are known to be involved in cell growth and differentiation. Aberrant expression or mutations in protein kinases have been shown to lead to uncontrolled cell proliferation, such as malignant tumor growth, and various defects in developmental processes, including cell migration and invasion, and angiogenesis. Protein kinases are therefore critical to the control, regulation, and modulation of cell proliferation in diseases and disorders associated with abnormal cell proliferation.
  • Protein kinases have also been implicated as targets in central nervous system disorders such as Alzheimer's disease, inflammatory disorders such as psoriasis, bone diseases such as osteoporosis, atherosclerosis, restenosis, thrombosis, metabolic disorders such as diabetes, and infectious diseases such as viral and fungal infections.
  • kinase regulation is cellular signaling from receptors at the cell surface to the nucleus.
  • the pattern of expression, ligand availability, and the array of downstream signal transduction pathways that are activated by a particular receptor determine the function of each receptor.
  • a pathway includes a cascade of kinases in which members of the growth factor receptor tyrosine kinases deliver signals via phosphorylation to other kinases such as Src tyrosine kinase, and the Raf, Mek and Erk serine/threonine kinase families. Each of these kinases is represented by several family members that play related but functionally distinct roles.
  • the loss of regulation of the growth factor signaling pathway is a frequent occurrence in cancer as well as other disease states (Fearon, Genetic Lesions in Human Cancer, Molecular Oncology 1996, 143-178).
  • VEGF vascular endothelial growth factor
  • VEGFR tyrosine kinases Suppression of formation of new blood vessels by inhibition of the VEGFR tyrosine kinases would have utility in a variety of diseases, including treatment of solid tumors, diabetic retinopathy and other intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, and endometriosis.
  • SAPK stress-activated protein kinase pathway
  • JNKs c-jun N-terminal kinases
  • the JNKs are mitogen-activated protein kinases (MAPKs) that are encoded by three distinct genes, jnk1, jnk2 and jnk3, which can be alternatively spliced to yield a variety of different JNK isoforms (Gupta et al., EMBO J 1996, 15, 2760).
  • the isoforms differ in their ability to interact with and phosphorylate their target substrates.
  • Activation of JNK is performed by two MAPK kinases (MAPKK), MKK4 and MKK7.
  • MKK4 is an activator of JNK as well as an additional MAPK, p38, while MKK7 is a selective activator of JNK.
  • MLK4 and MKK7 A number of MAPKK kinases are responsible for activation of MKK4 and MKK7, including the MEKK family and the mixed lineage kinase, or MLK family.
  • the MLK family is comprised of six members, including MLK1, MLK2, MLK3, MLK6, dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK).
  • MLK2 is also known as MST (Katoh, et al. Oncogene, 1994, 10, 1447).
  • kinases are proposed to be upstream of the MAPKKKs, including but not restricted to germinal center kinase (GCK), hematopoietic progenitor kinase (HPK), and Rac/cdc42.
  • GCK germinal center kinase
  • HPK hematopoietic progenitor kinase
  • Rac/cdc42 Rac/cdc42.
  • Specificity within the pathway is contributed, at least in part, by scaffolding proteins that bind selected members of the cascade.
  • JIP-1 JIP-1
  • binds HPK1, DLK or MLK3, MKK7 and JNK resulting in a module which enhances JNK activation (Dickens et al. Science 1997, 277, 693).
  • Manipulation of the activity of the SAPK pathway can have a wide range of effects, including promotion of both cell death and cell survival in response to various pro-apoptotic stimuli.
  • down-regulation of the pathway by genetic disruption of the gene encoding JNK3 in the mouse provided protection against kainic acid-induced seizures and prevented apoptosis of hippocampal neurons (Yang et al. Nature 1997, 389, 865).
  • inhibitors of the JNK pathway such as JIP-1 inhibit apoptosis (Dickens, supra).
  • the activity of the JNK pathway appears to be protective in some instances.
  • Thymocytes in which MKK4 has been deleted display increased sensitivity to CD95- and CD3 mediated apoptosis (Nishina et al. Nature 1997, 385, 350).
  • Overexpression of MLK3 leads to transformation of NIH 3T3 fibroblasts (Hartkamp et al. Cancer Res. 1999, 59, 2195).
  • An area the present invention is directed toward is identification of compounds that modulate the MLK members of the SAPK pathway and promote either cell death or cell survival.
  • Inhibitors of MLK family members would be anticipated to lead to cell survival and demonstrate therapeutic activity in a variety of diseases, including chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease and acute neurological conditions such as cerebral ischemia, traumatic brain injury and spinal injury.
  • Inhibitors of MLK members leading to inhibition of the SAPK pathway (JNK activity) would also display activity in inflammatory diseases and cancer.
  • MAP kinase family of proteins An additional member of the MAP kinase family of proteins is the p38 kinase. Activation of this kinase has been implicated in the production of proinflammatory cytokines such as IL-1 and TNF. Inhibition of this kinase could therefore offer a treatment for disease states in which disregulated cytokine production is involved.
  • CDKs cyclin dependent kinases
  • Inhibitors of kinases involved in mediating or maintaining particular disease states represent novel therapies for these disorders.
  • Examples of such kinases include Src, raf, the cyclin-dependent kinases (CDK) 1, 2, and 4 and the checkpoint kinases Chk1 and Cds1 in cancer, CDK2 or PDGF-R kinase in restenosis, CDK5 and GSK3 kinases in Alzheimer's Disease, c-Src kinase in osteoporosis, GSK3 kinase in type-2 diabetes, p38 kinase in inflammation, VEGFR 1-3 and TIE-1 and -2 kinases in angiogenesis, UL97 kinase in viral infections, CSF-1R kinase in bone and hematopoietic diseases, and Lck kinase in autoimmune diseases and transplant rejection.
  • CDK cyclin-dependent kinases
  • Structurally related compounds which are described as having activities other than PARP inhibition, are disclosed in WO 99/47522, EP 0695755, and WO 96/28447.
  • Other structurally related compounds, their syntheses and precursors are disclosed in Piers et al. J. Org. Chem. 2000, 65, 530, Berlinck et al. J. Org. Chem. 1998, 63, 9850, McCort et al. Tetrahedron Lett. 1999, 40, 6211, Mahboobi et al. Tetrahedron 1996, 52, 6363, Rewcastle et al. J. Med. Chem. 1996, 39, 918, Harris et al. Tetrahedron Lett.
  • PARP and kinase inhibitors are an important class of compounds requiring further discovery, exploration, and development. Although, a wide variety of PARP and kinase inhibitors are known, many suffer from problems such as toxicity, poor solubility, and limited efficacy, which prevent practical therapeutic use and preclude further development into effective drugs. Thus, there is a current and immediate need for new PARP and kinase inhibitors for the treatment of PARP and kinase related diseases. The present invention is directed to this, as well as other important ends.
  • the present invention is directed, in part, to novel multicyclic compounds. Specifically, in one embodiment, there are provided compounds of formula I: wherein constituent members of formula I are disclosed in detail, infra.
  • Another aspect of the invention relates to compounds of formula Ia: wherein constituent members of formula Ia are disclosed in detail, infra.
  • Another aspect of the invention relates to multicyclic compounds of formula IIa: wherein constituent members of formula Ia are disclosed in detail, infra.
  • a further aspect of the invention relates to compounds of formula IIaa: wherein constituent members of formula IIaa are disclosed in detail, infra.
  • multicyclic compounds of formula IIb wherein constituent members of formula IIb are disclosed in detail, infra.
  • multicyclic compounds of formula IIbb wherein constituent members of formula IIb are disclosed in detail, infra.
  • the present invention further encompasses a method of inhibiting PARP, VEGFR2, or MLK3 activity comprising contacting said PARP, VEGFR2, or MLK3 with a compound of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • a method for treating or preventing a neurodegenerative disease comprising administering to a mammal a therapeutically effective amount of a compound of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • a method for treating traumatic central nervous system injuries or preventing neuronal degradation associated with traumatic central nervous system injuries comprising administering to a mammal a therapeutically effective amount of a compound of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • a method for treating cerebral ischemia, cardiac ischemia, inflammation, endotoxic shock, or diabetes comprising administering to a mammal a pharmaceutically effective amount of a compound of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • a method for suppressing the formation of blood vessels in a mammal comprising administering to a mammal a pharmaceutically effective amount of a compound of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • a method for treating cellular proliferative disorders comprising administering to a mammal a pharmaceutically effective amount of a compound of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • a method for treating cancer comprising administering to a mammal a pharmaceutically effective amount of a compound of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • the present invention further encompasses a method of inhibiting PARP, VEGFR2, or MLK3 activity comprising contacting said PARP, VEGFR2, or MLK3 with compounds of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2.
  • a method for treating or preventing a neurodegenerative disease comprising administering to a mammal a therapeutically effective amount of a compound of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2.
  • a method for treating traumatic central nervous system injuries or preventing neuronal degradation associated with traumatic central nervous system injuries comprising administering to a mammal a therapeutically effective amount of a compound of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2.
  • a method for treating cerebral ischemia, cardiac ischemia, inflammation, endotoxic shock, or diabetes comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2.
  • a method for suppressing the formation of blood vessels in a mammal comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2.
  • a method for treating cellular proliferative disorders comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2.
  • a method for treating cancer comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • FIG. 1 shows a schematic including a compound within the scope of the present invention and precursors thereto.
  • FIG. 2 shows a general synthetic strategy for preparing compounds within the scope of the present invention.
  • FIG. 3 shows another general synthetic strategy for preparing compounds within the scope of the present invention.
  • FIG. 4 shows yet another general synthetic strategy for preparing compounds within the scope of the present invention.
  • FIG. 5 shows still another general synthetic strategy for preparing compounds within the scope of the present invention.
  • FIG. 6 shows yet another general synthetic strategy for preparing compounds within the scope of the present invention.
  • FIG. 7 shows a synthetic strategy for preparing benzimidazole derivatives within the scope of the present invention.
  • FIG. 8 shows a synthetic strategy for preparing compounds within the scope of the invention.
  • FIG. 9 shows synthetic strategy for preparing compounds within the scope of the present invention.
  • the present invention is directed, in part, to new multicyclic compounds that may be highly useful in connection with the inhibition of PARP, VEGFR2, MLK3, or other enzymes.
  • the new compounds are described in more detail below.
  • the present invention relates to novel multicyclic compounds of formula I: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • the present invention provides compounds of formula Ia: wherein:
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2;
  • the present invention includes compounds of formula I or Ia where E and F combined together with the carbon atoms to which they are attached, form a C 5 cycloalkyl group.
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • each of D 1 and D 2 is, independently,
  • each of X 1 and X 2 is, independently,
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2;
  • each of D 1 and D 2 is, independently,
  • each of X 1 and X 2 is, independently,
  • each of A and B is, independently,
  • each of A and B is, independently,
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • each of D 1 and D 2 is, independently,
  • each of X 1 and X 2 is, independently,
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • each of D 1 and D 2 is, independently,
  • each of X 1 and X 2 is, independently,
  • A is C( ⁇ O), CH 2 , CH(OR 3 ), or CH(SR 3 );
  • each E and F is, independently,
  • A is C( ⁇ O);
  • B is CH 2 ;
  • each A and B is, independently,
  • each A and B is, independently,
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • each of X 1 and X 2 is, independently,
  • compounds of formula III have E and F combined together with the atoms to which they are attached to form a C 5 cycloalkyl group.
  • each of A and B is, independently,
  • each of E and F is, independently,
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2;
  • each of X 1 and X 2 is, independently,
  • compounds of formula IIIa have E and F combined together with the atoms to which they are attached to form a C 5 cycloalkyl group.
  • Additional preferred embodiments of the compounds of formula III or IIIa include those where X 1 and X 2 are a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one substituent J.
  • X 1 and X 2 are a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one substituent J; and A and B are, independently C( ⁇ O) or CH 2 . More preferably, X 1 and X 2 are a substituted or unsubstituted pyridyl or pyrimidyl group, wherein said substituted pyridyl or pyrimidyl group has at least one substituent J; and A and B are C( ⁇ O).
  • each of A and B is, independently,
  • each of E and F is, independently,
  • V is N(R 1 ), O, or S;
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • each of A and B is, independently,
  • each of E and F is, independently,
  • V is N(R 1 ), O, or S;
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently,
  • each of J 1 and J 2 is, independently,
  • any two adjacent J groups can combine to form —X—(CH 2 ) p —X—, wherein X is independently O or NH, and p is 1 or 2;
  • Certain preferred embodiments include compounds of formula IV or IVa, wherein V is N(R 1 ); groups E and F, when taken together with the atoms to which they are attached, form a C 5 cycloalkyl group; and A and B are independently C( ⁇ O) or CH 2 .
  • Further preferred embodiments include compounds of formula IV, that may be particularly important with regard to inhibition of PARP, in which A and B are both CO, R 2 and J are both H, E and F, together with the atoms to which they are attached, form a cyclopentyl group, and V is either NH (1a, see Table 1) or N-(Lysine-2 HCl)(1k, see Table 1). Additionally, the compound of formula IV wherein A and B are both CO, R 2 is H, V is NH, E and F, together with the atoms to which they are attached, form a cyclopentyl group, and J is NH 2 CH 2 3-substituent (2p, see Table 2) comprises a further preferred embodiment.
  • Preferred embodiments of the present invention which may have particular relevance to the inhibition of VEGFR2 include compounds of formula IV in which both A and B are CO, E and F together are —CH ⁇ NCH ⁇ CH—, V is NH, R 2 is H, and J is either H (12a, see Table 5) or 3-CH 3 (12n, see Table 5).
  • Additional preferred embodiments of the compounds described herein include those where groups E and F, when taken together with the atoms to which they are attached, form a group other than imidazolyl.
  • Additional preferred embodiments of the compounds described herein include those where groups E and F, when taken together with the atoms to which they are attached, form a C 5 cycloalkyl group; X 1 and X 2 are a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one substituent J; and A and B are, independently C( ⁇ O) or CH 2 .
  • each of A and B is, independently,
  • R 1 is:
  • R 2 is:
  • each of R 3 and R 4 is, independently, hydrogen or lower alkyl
  • each of J 1 and J 2 is, independently,
  • J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
  • J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
  • J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
  • J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
  • J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
  • J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
  • each of A and B is, independently, C( ⁇ O);
  • R 1 is hydrogen
  • R 2 is hydrogen, lower alkyl or lower alkyl having at least one substituent J 4 ;
  • each of J 1 and J 2 is, independently,
  • J 4 is independently at each occurrence:
  • each of J 5 and J 6 is, independently,
  • J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
  • J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
  • J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
  • J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
  • each of A and B is, independently, C( ⁇ O);
  • R 1 is hydrogen or lower alkyl having at least one substituent J
  • R 2 is lower alkyl having at least one substituent J 4 ;
  • each of J 1 and J 2 is, independently,
  • J 4 is independently at each occurrence:
  • each of J 5 and J 6 is, independently,
  • each of J 5 and J 6 is, independently, lower alkyl, lower dialkylamino or heterocycloalkyl.
  • J 7 is hydrogen or heterocycloalkyl
  • J 4 is methylaminodimethyl, methylaminodiethyl, 4-methylmorpholine or 4-methylpiperazinyl-CH 2 .
  • J 4 is 4-methylpiperazinyl-CH 2 .
  • alkyl refers to a saturated straight, branched, or cyclic hydrocarbon of C 1 to C 20 .
  • Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, cyclopentyl, isopentyl, neopentyl, n-hexyl, isohexyl, cyclohexyl, cyclooctyl, adamantyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.
  • lower alkyl refers to a C 1 to C 6 saturated straight chain, branched, or cyclic hydrocarbon.
  • Lower alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, cyclopentyl, isopentyl, neopentyl, n-hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.
  • cycloalkyl and “C n cycloalkyl” are meant to refer to a monocyclic saturated or partially unsaturated hydrocarbon group.
  • C n in this context, wherein n is an integer, denotes the number of carbon atoms comprising the ring of the cycloalkyl group. For instance, C 6 cycloalkyl indicates a six-membered ring.
  • the bonds connecting the endocyclic carbon atoms of a cycloalkyl group may be single or part of a fused aromatic moiety, so long as the cycloalkyl group is not aromatic.
  • Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • heterocycloalkyl or “C n heterocycloalkyl” are meant to refer to a monocyclic saturated or partially unsaturated cyclic radical which, besides carbon atoms, contains at least one heteroatom as ring members.
  • heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms.
  • C n wherein n is an integer, denotes the number of carbon atoms comprising the ring, but is not indicative of the total number of atoms in the ring.
  • C 4 heterocycloalkyl includes rings with five or more ring members, wherein four of the ring members are carbon and the remaining ring members are heteroatoms.
  • bonds connecting the endocyclic atoms of a heterocycloalkyl group may be part of a fused aromatic moiety, so long as the heterocycloalkyl group is not aromatic.
  • heterocycloalkyl groups include, but are not limited to, 2-pyrrolidinyl, 3-pyrrolidinyl, piperdinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, and 3-tetrahydrothienyl.
  • aryl refers to a mono-, di-, tri-, or multinuclear aromatic ring system of 6 to 10 ring atoms. Non-limiting examples include phenyl, naphthyl, anthracenyl, and phenanthrenyl.
  • heteroaryl refers to an aromatic ring system having from 5 to 10 ring atoms comprising carbon and at least one heteroatom ring member such as an oxygen, nitrogen or sulfur.
  • the nitrogen heteroatom may be optionally oxidized for example pyridine-N-oxide or 1-oxy-pyridinyl.
  • Non-limiting examples are pyrryl, pyridinyl, furyl, 1,2,4-thiadiazolyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, purinyl, carbazolyl, benzimidazolyl, isoxazolyl, and acridinyl.
  • aralkyl is meant to refer to aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
  • lower aralkyl is meant to refer to aryl-substituted lower alkyl radicals.
  • Non-limiting examples include benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
  • aralkoxy is meant to refer to the group RO— wherein R is an aralkyl group as defined above.
  • lower aralkoxy is meant to refer to the group RO— wherein R is a lower aralkyl group as defined above.
  • alkoxy is meant to refer to RO—, wherein R is an alkyl group as defined above.
  • lower alkoxy is meant to refer to RO—, wherein R is a lower alkyl group as defined above.
  • Non-limiting examples include methoxy, ethoxy, and tert-butyloxy.
  • aryloxy is meant to refer to RO—, wherein R is an aryl group as defined above.
  • lower alkylamino and “lower dialkylamino” refer to an amino group that bears one or two lower alkyl substituents, respectively.
  • alkylamido is meant to refer to —C(O)NR— wherein R is an alkyl group as defined above.
  • dialkylamido is meant to refer to —C(O)NR′R′′ wherein R′ and R′′ are, independently, alkyl groups as defined above.
  • lower alkylamido is meant to refer to —C(O)NR— wherein R is a lower alkyl group as defined above.
  • lower dialkylamido is meant to refer to —C(O)NR′R′′ wherein R′ and R′′ are, independently, lower alkyl groups as defined above.
  • alkanoyl and “alkylcarbonyl,” as used herein, refer to RC(O)— wherein R is an alkyl group as defined above.
  • lower alkanoyl and “lower alkylcarbonyl” as used herein, refer to RC(O)— wherein R is a lower alkyl group as defined above.
  • alkanoyl groups include acetyl, trifluoroacetyl, hydroxyacetyl, propionyl, butyryl, valeryl, and 4-methylvaleryl.
  • arylcarbonyl refers to RC(O)— wherein R is an aryl group as defined above.
  • aryloxycarbonyl is meant to refer to ROC(O)— wherein R is an aryl group as defined above.
  • halo refers to fluoro, chloro, bromo, or iodo.
  • alkylsulfonyl is meant to refer to the group RSO 2 — wherein R is an alkyl group as defined above.
  • arylsulfonyl is meant to refer to the group RSO 2 — wherein R is an aryl group as defined above.
  • alkyloxycarbonylamino is meant to refer to the group ROC(O)N(H)— wherein R is an alkyl group as defined above.
  • lower alkyloxycarbonylamino is meant to refer to the group ROC(O)N(H)— wherein R is a lower alkyl group as defined above.
  • aryloxycarbonylamino is meant to refer to the group ROC(O)N(H)— wherein R is an aryl group as defined above.
  • sulfonylamido is meant to refer to the group —SO 2 C(O)NH—.
  • alkylsulfonylamido is meant to refer to the group RSO 2 C(O)NH— wherein R is an alkyl group as defined above.
  • arylsulfonylamido is meant to refer to the group RSO 2 C(O)NH— wherein R is an aryl group as defined above.
  • lower alkyl ester of phosphonic acid is meant to refer to the group —P(O)(OR′)(OR′′) wherein R′ and R′′ are lower alkyl as defined above.
  • aryl ester of phosphonic acid is meant to refer to the group —P(O)(OR′)(OR′′) wherein R′ and R′′ are aryl as defined above.
  • aminocarbonyloxy is meant to refer to the group RR′N—C(O)—O— wherein R and R′ are an alkyl group as defined above.
  • arylaminocarbonyloxy is meant to refer to the group Ar—N(R)—C(O)—O— wherein Ar is aryl, as defined above, and R is an alkyl group as defined above.
  • heteroarylaminocarbonyloxy is meant to refer to the group het-Ar—N(R)—C(O)—O— wherein het-Ar is heteroaryl, as defined above, and R is an alkyl group as defined above.
  • amino acid means a molecule containing both an amino group and a carboxyl group. It includes an “ ⁇ -amino acid” which is well known to one skilled in the art as a carboxylic acid that bears an amino functionality on the carbon adjacent to the carboxyl group. Amino acids can be naturally occurring or non-naturally occurring.
  • Proteins refer to amino acids, as described above, comprising protecting groups.
  • the amino group of an amino acid may be protected with t-butoxycarbonyl or benzyloxycarbonyl groups.
  • the carboxyl group of the amino acid may be protected as alkyl and aralkyl esters.
  • alcohol groups of amino acids can be protected as alkyl ethers, aralkyl ethers, and silyl ethers.
  • endocyclically comprising is meant to describe a cyclic chemical moiety that includes a specified chemical group as a ring forming member.
  • a furanyl group endocyclically comprises an oxygen atom because the oxygen atom is a member of the ring structure.
  • groups E and F may be combined together with the atoms to which they are attached to form a heterocycloalkyl group.
  • This heterocycloalkyl group may endocyclically comprise the chemical group G, meaning that at least one atom of group G is a ring forming member.
  • E and F may be combined together with the atoms to which they are attached to form the heterocycloalkyl group endocyclically comprising group G, wherein G, in this instance, is N(CH 3 ).
  • terapéuticaally effective amount is meant to refer to an amount of compound of the present invention that will elicit a desired therapeutic or prophylactic effect or response when administered according to the desired treatment regimen.
  • contacting means bringing together, either directly or indirectly, one or more molecules with another, thereby facilitating intermolecular interactions. Contacting may occur in vitro, ex vivo, or in vivo.
  • cellular proliferative disorders is meant to refer to malignant as well as non-malignant cell populations which differ from the surrounding tissue both morphologically and genotypically.
  • Types of cellular proliferative disorders include, for example, solid tumors, cancer, diabetic retinopathy, intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, and endometriosis.
  • the present invention features methods for preparing the multicyclic compounds described herein which are useful as inhibitors of PARP, VEGFR2, and MLK3.
  • the method consists of a multistep synthesis starting with the necessary heterocyclic compounds.
  • FIG. 1 outlines the general synthesis of compounds of the present invention for the case when the heterocyclic starting material is an indole.
  • an indole A which is unsubstituted or substituted in positions 4-7 on the indole ring, is treated serially, for example, with butyllithium, carbon dioxide, t-butyllithium and a ketone B (having substituents E and F) to provide a 2-substituted indolyl tertiary alcohol C.
  • This tertiary alcohol is eliminated, for example, under acidic conditions using hydrochloric acid or toluenesulfonic acid, to afford a substituted 2-vinylindole, D.
  • Diels-Alder cycloaddition of D with a dienophile such as, but not limited to, maleimide (E) affords the cycloaddition intermediate F.
  • Aromatization of the cycloaddition intermediate for example, with oxygen in the presence of a catalyst such as palladium or platinum or with an oxidant such as DDQ or tetrachloroquinone, produces carbazole G.
  • carbazole G contains bromoacetyl or substituted 2-bromoacyl substituents, as shown in FIG. 4 , the bromine can be displaced by various nucleophiles to give further embodiments of the present invention.
  • the 2-bromoacyl group may be reacted with various thioamides to give substituted thiazoles.
  • dienophiles other than maleimide (E) may be used in the Diels-Alder reaction, and include for example, dialkyl fumarate, fumaric acid, dialkyl maleate, maleic acid, maleic anhydride, dialkyl acetylenedicarboxylate or alkyl 3-cyanoacrylate.
  • the intermediates resulting from cycloaddition with these dienophiles give imides, or the corresponding lactams as shown in FIG. 5 .
  • anyhdrides obtained from maleic anhydride cycloaddition or by dehydration of diacids, afford imides when treated with bis(trimethylsilyl)amine or urea.
  • the anhydrides afford six-membered hydrazones when treated with hydrazine.
  • the lactams are obtained by separating the cyano ester isomers, aromatizing each isomer, and reducing the cyano ester to the lactam, as shown in FIG. 5 .
  • Imides may also be reduced to lactams by well established methods known to those skilled in the art.
  • Indole-type compounds of the present invention are prepared according to the scheme shown in FIG. 6 .
  • substituted vinyl pyrrole starting materials are prepared by the reaction of a pyrrole with an enamine of a ketone as described in the literature ( Heterocycles 1974, 2, 575-584).
  • a substituted 2-vinyl pyrrole is reacted with various dienophiles, such as those described above, to afford a cycloaddition intermediate which is a precursor to embodiments of the present invention.
  • a nitrogen protecting group such as a silyl protecting group, particularly triisopropyl silyl, may used throughout as depicted in FIG. 6 .
  • heterocyclic precursors may be prepared by analogous reactions.
  • a substituted 5-vinyl imidazole is reacted with various dienophiles, such as those described above, to afford a cycloaddition intermediate which can be further modified by reactions well known to those skilled in the art to give benzimidazole precursors.
  • a substituted 5-vinyl 1,2,3-triazole or 4-vinyl thiazole can be reacted with various dienophiles as above to also afford cycloaddition intermediates leading to embodiments of the invention.
  • the benzimidazole-type compounds of the present invention can also be prepared according to the method shown in FIG. 7 , in which preformed benzimidozoles serve as starting materials.
  • an optionally substituted 2-vinyl benzofuran or 2-vinyl benzothiophene can be reacted with various dienophiles, such as those listed previously, to afford a cycloaddition intermediate. Modification of the cycloaddition intermediate can lead to imides, lactams, and related compounds of the present invention.
  • the compounds of the present invention are PARP inhibitors.
  • the potency of the inhibitor can be tested by measuring PARP activity in vitro or in vivo.
  • a preferred assay monitors transfer of radiolabeled ADP-ribose units from [ 32 P]NAD + to a protein acceptor such as histone or PARP itself. Routine assays for PARP are disclosed in Purnell and Whish, Biochem. J 1980, 185, 775, incorporated herein by reference.
  • the compounds of the present invention are also VEGFR2 or MLK3 inhibitors.
  • the potency of the inhibitor can be tested by measuring VEGFR2 or MLK3 activity in vitro or in vivo.
  • a preferred assay for VEGFR2 kinase activity involves the phosphorylation of a protein substrate immobilized on a microtiter plate. The resulting phosphotyrosine residue is detected with an anti-phosphotyrosine antibody conjugated to a europium chelate, allowing quantitation of the product by time-resolved fluorometry. Similar assay methods have been employed for the detection of the tyrosine kinase c-src, as described in Braunwalder et al. Anal. Biochem.
  • a preferred assay method for MLK3 utilizes phosphorylation of a protein substrate, such as myelin basic protein, with [ ⁇ - 32 P]ATP, followed by isolation of the acid-insoluble 32 P-phosphoprotein product on a filtration plate. Analogous methods were employed for the assay of protein kinase C, as reported in Pitt and Lee, J. Biomol. Screening 1996, 1, 47, incorporated herein by reference.
  • Enzyme activity can be reduced or inhibited by contacting the enzyme with at least one compound described herein.
  • the contacting can occur either in vitro, in vivo, or ex vivo.
  • Contacting can also be promoted by use of contacting media which enhances the rate of mixing of enzyme and inhibitor.
  • Preferred media include water, water-based solutions, buffered solutions, water-miscible solvents, enzyme-solubilizing solutions, and any combination thereof.
  • Contacting cells containing the enzyme in vivo preferably employs the inhibitor to be delivered in proximity to the enzyme associated with the cell in a biologically compatible medium.
  • Preferred biologically compatible media include water, water-based solutions, saline, biological fluids and secretions, and any other non-toxic material that may effectively deliver inhibitor to the vicinity of the enzyme in a biological system.
  • the compounds described herein can be used to prevent or treat the onset or progression of any disease or condition related to PARP activity in mammals, especially humans.
  • Such conditions include traumatic injury to the central nervous system, such as brain and spinal cord injuries, and the neuronal degradation associated with traumatic injury to the central nervous system.
  • Related conditions and diseases treatable by methods of the present invention include vascular strokes, cardiac ischemia, cerebral ischemia, cerebrovascular disorders such as multiple sclerosis, and neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases.
  • PARP related conditions or diseases treatable by the compounds described herein include inflammation such as pleurisy and colitis, endotoxic shock, diabetes, cancer, arthritis, cardiac ischemia, retinal ischemia, skin aging, chronic and acute pain, hemorrhagic shock, and others.
  • a patient can be administered one or more compounds described herein to prevent or minimize damage to the brain.
  • Patients with symptoms of Alzheimer's, Huntington's, or Parkinson's disease can be treated with compounds of the present invention to halt the progression of the disease or alleviate symptoms.
  • PARP inhibitors may also be used to treat patients suffering from cancer. For instance, cancer patients can be administered the present compounds in order to augment the anti-tumor effects of chemotherapy.
  • the compounds described herein can be used to prevent or treat the progression of any disease or condition related to kinase activity (such as VEGFR2 or MLK3 activities) in mammals, especially humans.
  • the compounds described herein may be used to treat conditions related to MLK3 activity such as chronic neurodegenerative diseases as, for example, Alzheimer's disease, Parkinson's disease, and Huntington's disease, and acute neurological conditions such as cardiac ischemia, cerebral ischemia, as well as traumatic brain and spinal injuries.
  • the compounds described herein can also be useful in the treatment of inflammatory diseases and cancer related to MLK3 activity.
  • the compounds described herein can be used to inhibit VEGFR2 which may lead to suppression of formation of new blood vessels.
  • Such compounds can therefore be useful in the treatment of conditions associated with new blood vessel formations such as, for example, solid tumors, diabetic retinopathy, and other intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, and endometriosis.
  • Dosage may vary depending on the compound, the potency of the compound, the type of disease, and the diseased state of the patient, among other variables. Dosage amount can be measured by administration of pre-measured dosing means or unit dosages in the form of tablets, capsules, suppositories, powders, emulsions, elixirs, syrups, ointments, creams, or solutions.
  • PARP or kinase inhibitors may be administered by any route that drugs are conventionally administered.
  • routes of administration include intraperitoneal, intravenous, intramuscular, subcutaneous, intrathecal, intracheal, intraventricular, oral, buccal, rectal, parenteral, intranasal, transdermal or intradermal. Administration may be systemic or localized.
  • compositions will generally include an inert diluent carrier or an edible carrier.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • Tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or
  • dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings, and flavorings.
  • Alternative preparations for administration include sterile aqueous or nonaqueous solutions, suspensions, and emulsions.
  • nonaqueous solvents are dimethylsulfoxide, alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include mixtures of alcohols and water, buffered media, and saline.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases, and the like.
  • Preferred methods of administration of the present compounds to mammals include intraperitoneal injection, intramuscular injection, and intravenous infusion.
  • Various liquid formulations are possible for these delivery methods, including saline, alcohol, DMSO, and water based solutions.
  • the concentration of inhibitor may vary according to dose and volume to be delivered and can range from about 1 to about 1000 mg/mL.
  • Other constituents of the liquid formulations can include, preservatives, inorganic salts, acids, bases, buffers, nutrients, vitamins, or other pharmaceuticals such as analgesics or additional PARP and kinase inhibitors.
  • Particularly preferred formulations for administration of the present compounds are detailed in the following publications that describe administration of known PARP inhibitors and are incorporated herein by reference in their entireties; Kato, T.
  • Compounds of the present invention also may take the form of a pharmacologically acceptable salt, hydrate, solvate, or metabolite.
  • Pharmacologically acceptable salts include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like.
  • suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like.
  • PARP activity was monitored by transfer of radiolabeled ADP-ribose units from [ 32 P]NAD + to a protein acceptor such as histone or PARP itself.
  • the assay mixtures contained 100 mM Tris (pH 8.0), 2 mM DTT, 10 mM MgCl 2 , 20 ug/ml DNA (nicked by sonication), 20 mg/ml histone H1, 5 ng recombinant human PARP, and inhibitor or DMSO ( ⁇ 2.5% (v/v)) in a final volume of 100 uL.
  • the reactions were initiated by the addition of 100 ⁇ M NAD + supplemented with 2 uCi [ 32 P]NAD + /mL and maintained at room temperature for 12 minutes.
  • a 96-well FluoroNUNC MaxiSorp plate was coated with 100 ⁇ L/well of recombinant human PLC- ⁇ /GST substrate solution at a concentration of 40 ⁇ g/mL in Tris-buffered saline (TBS).
  • TBS Tris-buffered saline
  • the VEGFR2 activity was assayed in a 100 ⁇ L assay mixture containing 50 mM HEPES (pH 7.4), 30 ⁇ M ATP, 10 mM MnCl 2 , 0.1% BSA, 2% DMSO, and 150 ng/mL recombinant human baculovirus-expressed human VEGFR2 cytoplasmic domain (prephosphorylated for 60 min at 4° C.
  • the time-resolved fluorescence of the resulting solution was measured using the BMG PolarStar (Model #403) using excitation and emission wavelengths of 340 nm and 615 nm, respectively, a collection delay of 400 ⁇ sec and an integration time of 400 ⁇ sec.
  • the activity assay for MLK3 was performed in Millipore Multiscreen plates. Each 50 ⁇ L assay mixture contained 50 mM HEPES (pH 7.0), 1 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 25 mM ⁇ -glycerophosphate, 100 ⁇ M ATP, 1 ⁇ Ci [ ⁇ - 32 P]ATP, 0.1% BSA, 500 ⁇ g/mL myelin basic protein, 2% DMSO various concentrations of test compounds, and 2 ⁇ g/mL of baculoviral human GST-MLK1 kinase domain. Samples were incubated for 15 min at 37° C.
  • the reaction was stopped by adding ice-cold 50% TCA and the proteins were allowed to precipitate for 30 min at 4° C.
  • the plates were allowed to equilibrate for 1-2 hours prior to counting in the Wallac MicroBeta 1450 Plus scintillation counter.
  • Examples 5 to 10 present PARP, VEGFR2, and MLK3 inhibiting data for compounds of the present invention.
  • IC 50 values were determined as described in Examples 1 and 2.
  • inhibiting data is presented as percent inhibition at a specified concentration.
  • Compounds are tabulated together with compound number, substituents, and enzyme inhibition data.
  • Methods and materials employed in the synthesis of starting materials, intermediates, and inhibitors are as follows. Thin layer chromatography was performed on silica gel plates (MK6F 60A, size 1 ⁇ 3 in, layer thickness 250 mm; Whatman Inc., Whatman House, UK). Preparative thin layer chromatography was performed on silica gel plates (size 20 ⁇ 20 in, layer thickness 1000 micron; Analtech, Newark, N.J.). Preparative column chromatography was carried out using Merck, Whitehouse Station, N.J., silica gel, 40-63 mm, 230-400 mesh.
  • 1 H NMR spectra were recorded on a GE QE Plus instrument (300 MHz) using tetramethylsilane as an internal standard. Electrospray mass spectra were recorded on a VG platform II instrument. (Fisons Instruments).
  • FIG. 1 depicts the syntheses of intermediates, precursors, and starting materials for compounds of the present invention. The synthesis of 1a is also depicted therein.
  • Compound F is characterized as a yellow amorphous solid; 1 H-NMR (DMSO-d 6 ) ⁇ 11.15 (s, 1H), 10.89 (s, 1H), 7.65 (d, 1H), 7.23 (d, 2H), 6.91 (m, 2H), 4.24 (d, 1H), 3.30 (m, 2H), 2.60 (m, 1H), 2.14 (m, 1H) 1.92 (m, 1H), 1.45 (m, 3H), 1.13 (m, 1H). MS m/e 279 (M ⁇ H) ⁇ .
  • Compound G (1a, 5,7,8,9,10,11-hexahydrocyclopent[a]pyrrolo[3,4-c]carbazole-5(6H),7-dione) was prepared in the following manner. A mixture of compound F (10.20 g, 36.42 mmol), DDQ (20.7 g, 91.18 mmol), and toluene (100 mL) was heated at 60° C. in a sealed tube overnight, cooled to room temperature and filtered. The filtrate was washed several times with methanol (total volume 250 mL) to remove all the by-products. Drying under high vacuum generated 7.8 g of compound G (1a) that was used without any further purification.
  • Compound G also identified as 1a, occurs as a yellow amorphous solid showing R t 10.90 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.80 (s, 1H), 10.90 (s, 1H), 8.70 (s, 1H), 7.50 (m, 2H), 7.20 (t, 1H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H); MS m/e 275 (M ⁇ H).
  • Compound 1b is characterized as a yellow amorphous solid; R t 17.92 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.90 (s, 1H), 8.70 (d, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 7.10 (m, 5H), 4.30 (s, 2H), 3.70 (t, 2H), 3.50 (t, 2H), 3.25 (2 sets of t, 4H), 2.25 (m, 2H), 1.80 (m, 2H); MS m/e 423 (M ⁇ H).
  • 1c is characterized as a yellow amorphous solid; R t 14.31 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.90 (s, 1H), 8.70 (d, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 3.70 (t, 2H), 3.25 (2 sets of t, 4H), 2.50 (t, 2H), 2.25 (m, 2H), 1.90 (m, 2H); MS m/e 342 (M ⁇ H).
  • Compound 1d is characterized as a yellow amorphous solid; R t 16.59 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.90 (s, 1H), 8.70 (d, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 3.70 (m, 4H), 3.25 (2 sets oft, 4H), 2.25 (m, 2H), 2.10 (m, 2H); MS m/e 351 and 353 (M ⁇ H for different isotopes of chlorine).
  • Compound 1e is characterized as a yellow amorphous solid; R t 12.18 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.90 (s, 1H), 8.70 (d, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 3.70 (t, 2H), 3.50 (t, 2H), 3.40 (broad, 1H), 3.25 (2 sets of t, 4H), 2.25 (m, 2H), 1.80 (m, 2H); MS m/e 333 (M ⁇ H).
  • Compound 1g is characterized as a yellow amorphous solid; R t 12.91 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.90 (s, 1H), 8.70 (d, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 3.70 (t, 2H), 3.25 (m, 6H), 2.25 (m, 10H), 1.80 (m, 2H); MS m/e 404 (M+H).
  • Compound 1h is characterized as a yellow amorphous solid; R t 10.47 min; 1 H-NMR (CDCl 3 ) ⁇ 9.00 (d, 1H), 8.30 (s, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 3.70 (t, 2H), 3.30 (t, 2H), 3.10 (t, 2H), 2.25 (m, 6H), 2.30 (m, 2H), 1.90 (m, 2H), 1.00 (t, 6H); MS m/e 390 (M+H).
  • Compound 1j is characterized as a yellow amorphous solid; R t 16.19 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.10 (s, 1H), 8.70 (d, 1H), 8.10 (d, 2H), 7.70 (m, 3H), 7.50 (m, 2H), 7.30 (t, 1H), 3.25 (2 sets oft, 4H), 2.25 (m, 2H); MS m/e 415 (M ⁇ H).
  • Compound 1k is characterized as a yellow amorphous solid; R t 5.93 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 8.80 (d, 1H), 8.70 (broad, 3H), 8.00 (broad, 3H), 7.60 (m, 2H), 7.30 (t, 1H), 5.00 (broad, 1H), 3.25 (m, 4H), 2.70 (broad, 2H), 2.25 (m, 2H), 2.00 (2 sets of broad, 2H), 1.50 (broad m, 4H); MS m/e 406 (M+2H).
  • This compound was prepared following the same procedure as described before for the synthesis of 1k. Thus, starting from 0.1 g of 1a and 0.14 g of Boc-beta-alanine, 0.025 g of 1l was obtained. 1l is characterized as a yellow amorphous solid; R t 7.45 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 8.70 (d, 1H), 8.00 (broad, 3H), 7.50 (m, 2H), 7.25 (t, 1H), 3.30 (t, 2H), 3.25 (m, 6H), 2.25 (m, 2H); MS m/e 348 (M+H).
  • Compound 1p is characterized as a yellow amorphous solid; R t 14.59 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 8.50 (d, 1H), 7.50 (m, 2H), 7.25 (m, 6H), 5.10 (s, 2H), 4.50 (s, 2H), 3.25 (m, 4H), 2.25 (m, 2H); MS m/e 423 (M ⁇ H).
  • Compound 1n is characterized as a yellow amorphous solid; R t 14.62 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.90 (s, 1H), 8.50 (d, 1H), 7.50 (m, 2H), 7.20 (m, 6H), 4.50 (s, 2H), 3.70 (overlapping dd, 2H), 3.60 (overlapping dd, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H); MS m/e 409 (M ⁇ H).
  • Compound 1o is characterized as a yellow amorphous solid; R t 9.06 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.90 (s, 1H), 8.75 (d, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 3.60 (t, 2H), 3.25 (2 sets oft, 4H), 2.60 (t, 2H), 2.50 (q, 4H), 2.25 (m, 2H), 0.80 (t, 6H); MS m/e 376 (M+H).
  • Compound 1p is characterized as a yellow amorphous solid; R t 10.36 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 8.75 (d, 1H), 7.50 (m, 2H), 7.25 (t, 1H), 4.25 (s, 2H), 4.00-3.00 (broad, 1H), 3.25 (m, 4H), 2.25 (m, 2H); MS m/e 333 (M ⁇ H).
  • the bis(t-butoxycarbonyl)-lysyl derivative was prepared as described for 1k, and purified by chromatography (CH 2 Cl 2 -Et 2 O) to give a yellow glass. MS m/e 613 (M+Na) + .
  • the product is characterized as a yellow amorphous solid with properties; R t 12.39 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 8.70 (s, 1H), 7.60 (d, 1H), 7.50 (d, 1H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H); MS m/e 353 and 355 (M ⁇ H for different isotopes of bromine).
  • Compound 2b is a yellow amorphous solid; R t 14.06 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 8.70 (s, 1H), 7.50 (m, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H); MS m/e 309 and 301 (M ⁇ H for different isotopes of chlorine).
  • this compound was prepared following the same multistep procedure as described for the synthesis of 1a from indole.
  • the compound 2c is characterized as an orange amorphous solid; R t 11.50 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 8.50 (d, 1H), 7.50 (m, 1H), 7.30 (t, 1H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H). MS m/e 293 (M ⁇ H).
  • This compound was prepared following the same procedure as described before for the synthesis of 2d. Thus, starting from 0.050 g of 1a and 0.10 g of bromoacetyl bromide, 0.045 g of 2e was obtained. 2e is characterized as a yellow amorphous solid; R t 10.76 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.30 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.10 (d, 1H), 7.60 (d, 1H), 4.80 (s, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H). MS m/e 396 (M ⁇ H).
  • This compound was prepared following the same procedure as described before for the synthesis of 2e. Based on 0.2 g of 1a starting material, 0.2 g of 2f was obtained. The compound 2f is characterized as a yellow amorphous solid; R t 11.96 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.50 (s, 1H), 8.20 (d, 1H), 7.50 (d, 1H), 5.70 (q, 1H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 1.80 (d, 3H). MS m/e 410 (M ⁇ H).
  • Compound 2g is characterized as a yellow amorphous solid; R t 5.77 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.25 (s, 1H), 11.00 (s, 1H), 9.50 (s, 1H), 8.20 (d, 1H), 7.50 (d, 1H), 3.70 (s, 2H), 3.25 (2 sets of t, 4H), 2.50 (broad, 4H), 2.25 (broad m, 6H), 2.10 (t, 3H). MS m/e 417 (M+H).
  • Compound 2h is characterized as a yellow amorphous solid; R t 6.50 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.25 (s, 1H), 11.00 (s, 1H), 9.50 (s, 1H), 8.20 (d, 1H), 7.60 (d, 1H), 3.70 (s, 2H), 3.50 (broad, 4H), 3.25 (2 sets of t, 4H), 2.40 (broad, 4H), 2.25 (broad m, 2H); MS m/e 404 (M+H).
  • Compound 2i is characterized as a yellow amorphous solid; R t 7.32 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.25 (broad, 1H), 11.00 (broad, 1H), 9.50 (s, 1H), 8.20 (d, 1H), 7.50 (d, 1H), 3.50 (s, 2H), 3.25 (2 sets of t, 4H), 2.40 (broad, 4H), 2.25 (broad m, 2H), 1.50 (broad, 4H), 1.30 (broad, 2H). MS m/e 402 (M+H).
  • Compound 2j is characterized as a dark brown amorphous solid; R t 7.04 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.25 (broad, 1H), 11.00 (broad, 1H), 9.50 (s, 1H), 8.20 (d, 1H), 7.50 (d, 1H), 3.70 (s, 2H), 3.25 (2 sets of t, 4H), 2.60 (q, 4H), 2.25 (broad m, 2H), 1.00 (t, 6H). MS m/e 390 (M+H).
  • Compound 2k is characterized as a yellow amorphous solid; R t 9.20 min (broad); 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.20 (d, 1H), 7.60 (d, 1H), 4.10 (s, 2H), 3.40 (s, 2H), 3.25 (2 sets of t, 4H), 2.40 (s, 3H), 2.25 (broad m, 2H), 1.40 (s, 9H); MS m/e 461 (M+H).
  • Compound 2l is characterized as a yellow amorphous solid; R t 6.34 min (broad); 1 H-NMR (DMSO-d 6 ) ⁇ 2.20 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.10 (d, 1H), 7.60 (d, 1H), 4.70 (s, 2H), 3.70 (s, 2H), 3.50 (broad, 2H), 3.25 (2 sets of t, 4H), 2.70 (s, 3H), 2.25 (broad m, 2H); MS m/e 406 (M+H).
  • Compound 2n is characterized as a yellow amorphous solid; R t 9.28 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.50 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.50 (s, 1H), 8.20 (d, 1H), 8.00 (s, 1H), 7.50 (d, 1H), 6.00 (s, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H); MS m/e 386 (M+H).
  • CuCN method A mixture of 2a (0.1 g, 0.28 mmol), CuCN (0.075 g, 0.85 mmol) and 1-methyl-2-pyrrolidinone (4 mL) was heated at 175° C. in a sealed tube overnight, cooled to room temperature, passed through a silica pad, concentrated to a small volume and poured into water (20 mL). The precipitated solid was filtered, washed with water, dried and purified by column chromatography (eluant: EtOAc) to generate 0.006 g of 2o.
  • EtOAc column chromatography
  • Zn(CN) 2 method A mixture of 2a (2.33 g, 6.56 mmol) and Zn(CN) 2 (1.56 g, 13.3 mmol) were dissolved in DMF (22 mL) under nitrogen. Pd(Ph 3 P) 4 (1.17 g, 0.10 mmol, 15 mol %) was added, and the mixture was stirred at 125° C. for 80 min. The warm solution was vacuum filtered through Celite® and the pad rinsed with hot DMF. The filtrate was diluted with two volumes of water.
  • EDCI (30 mg, 0.156 mmol) was added to a suspension of 3-(aminomethyl)-5,7,8,9,10,11-hexahydrocyclopent[a]pyrrolo[3,4-c]carbazole-5(6H),7-dione hydrochloride (2p, 31 mg, 0.10 mmol), NMM (15 uL, 13 mmol), HOBT-H 2 O (16 mg, 0.10 mmol), and acetic acid (10 mg, 0.17 mmol) in DMF (0.5 mL). All solids dissolved 10 min. After 2 days, water (4 mL) was added.
  • NMM 14 mg, 0.14 mmol was added to a mixture of 3-(aminomethyl)-5,7,8,9,10,11-hexahydrocyclopent[a]pyrrolo[3,4-c]carbazole-5(6H),7-dione hydrochloride (2p, 15 mg, 0.045 mmol) and di-t-butyl dicarbonate (18 mg, 0.082 mmol) in DMF (1 mL). After 2 hr, the mixture was filtered, and water (5 mL) was added. The precipitate was collected and rinsed with 3% citric acid, saturated NaHCO 3 , and water, then dried to afford the product (12 mg, 67% yield) as a golden-brown solid.
  • Compound 2ae is a yellow amorphous solid; R t 4.89 min (broad); 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.10 (s, 1H), 7.75 (d, 1H), 7.40 (d, 1H), 3.25 (2 sets of t, 4H), 2.50 (s, 1H), 2.25 (broad m, 2H); MS m/e 355 (M ⁇ H).
  • example 2ag (20 mg, 0.065 mmol) in DMF (3 ml) was added 1-hydroxybenzotriazole (HOBt, 13 mg, 0.098 ) and benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP, 43 mg, 0.098 mmol).
  • HOBt 1-hydroxybenzotriazole
  • BOP benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate
  • the precipitate was collected by vacuum filtration and rinsed with water, 1M HCl, and water, then dried to give 1.11 g (95% yield) of crude 2bd contaminated with 17% of the dimeric ketone.
  • a pure sample of 2bd was obtained by suspension in dilute aqueous Na 2 CO 3 and filtration followed by acidification with HCl. After several days, the resulting gel yielded a solid precipitate which was collected and dried.
  • Oxalyl chloride (0.010 mL, 14.5 mg, 0.114 mmol) was added to crude 2bd (28 mg, 0.0875 mmol) in DMF (0.28 mL) 0° C. After 1 h at 20° C., excess HCl was removed with a nitrogen stream, and 2-(N,N-dimethylamino)ethylamine (24 mg, 0.27 mmol) was added. After 1 h, the precipitate was collected, dried, and suspended in 0.5 mL 0.1 M HCl. The precipitate (consisting of dimeric ketone in the crude starting material) was discarded and the supernatant was lyophilized to give the hydrochloride of 2cg.
  • Compound 3a is characterized as a yellow amorphous solid; R t 6.68 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.00 (s, 1H), 7.75 (d, 1H), 7.50 (d, 1H), 7.00 (s, 1H), 3.50 (broad, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H). MS m/e 375 (M+H).
  • Compound 3b is characterized as a yellow amorphous solid; R t 10.14 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.00 (d, 1H), 7.70 (s, 1H), 7.50 (d, 1H), 3.25 (2 sets of t, 4H), 2.70 (s, 3H), 2.25 (broad m, 2H); MS m/e 374 (M+H).
  • Compound 3e is characterized as a yellow amorphous solid; R t 12.23 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 10.90 (s, 1H), 9.20 (s, 1H), 8.20 (broad, 3H), 8.00 (d, 1H), 7.80 (broad, 1H), 7.50 (d, 1H), 6.80 (s, 1H), 4.00 (m, 1H), 3.50 (broad, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 1.70 (broad, 4H); MS m/e 646 (M+H).
  • Compound 3c is characterized as a yellow amorphous solid; R t 12.90 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 10.90 (s, 1H), 9.40 (s, 1H), 8.00 (d, 1H), 7.60 (s, 1H), 3.25 (2 sets of t, 4H), 2.70 (s, 3H), 2.25 (broad m, 2H); MS m/e 452 and 454 (M+H for different isotopes of bromine).
  • Example 2f (0.1 g, 0.24 mmol), thiourea (0.03 g, 0.4 mmol) and ethanol (3 mL) was heated at 75-80° C. in a sealed tube overnight. On cooling, a precipitate appeared that was filtered, washed several times with cold ethanol and ether and dried under high vacuum to generate 0.075 g of 3d.
  • Compound 3d is characterized as a yellow amorphous solid; R t 8.07 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.00 (s, 1H), 8.80 (b, 2H), 7.70 (dd, 2H), 3.25 (2 sets of t, 4H), 2.40 (s, 3H), 2.25 (broad m, 2H). MS m/e 389 (M+H).
  • Compound 3g is characterized as a yellow amorphous solid; R t 8.25 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 10.90 (s, 1H), 9.30 (s, 1H), 8.20 (broad, 4H), 8.00 (d, 1H), 7.60 (d, 1H), 7.50 (s, 1H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H); MS m/e 417 (M+H).
  • Compound 3h is characterized as a yellow amorphous solid; R t 7.92 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.10 (s, 1H), 7.80 (d, 1H), 7.50 (d, 1H), 7.00 (s, 1H), 3.75 (broad, 1H), 3.25 (2 sets of t, 4H), 2.40 (s, 3H), 2.25 (broad m, 2H). MS m/e 389 (M+H).
  • Compound 3i is characterized as a yellow amorphous solid; R t 10.57 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.00 (d, 1H), 7.60 (d, 1H), 7.40 (s, 1H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 2.10 (s, 3H). MS m/e 415 (M ⁇ H).
  • Compound 3j is characterized as a brown amorphous solid; R t 12.81 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.30 (t, 1H), 8.00 (d, 1H), 7.80 (s, 1H), 7.60 (d, 1H), 7.30 (m, 5H), 5.00 (s, 2H), 4.50 (broad, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H). MS m/e 545 (M+Na), 523 (M+H).
  • Compound 3k is characterized as a yellow amorphous solid; R t 7.36 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.60 (broad, 3H), 8.10 (d, 1H), 8.00 (s, 1H), 7.60 (d, 1H), 4.50 (broad, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H). MS m/e 389 (M+H).
  • Compound 3l is characterized as a brown amorphous solid; R t 7.41 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.80 (s, 1H), 11.60 (s, 1H), 11.30 (s, 1H), 10.80 (s, 1H), 9.10 (s, 1H), 7.80 (d, 1H), 7.50 (d, 1H), 7.20 (s, 1H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 2.10 (s, 3H). MS m/e 400 (M+H).
  • Compound 3m is characterized as a yellow amorphous solid; R t 9.95 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.10 (m, 2H), 7.80 (s, 1H), 7.60 (d, 1H), 4.50 (s, 2H), 3.25 (2 sets of t, 4H), 2.40 (s, 3H), 2.25 (broad m, 2H). MS m/e 489 (M+Na), 467 (M+H).
  • the compound 3n is characterized as a yellow amorphous solid; R t 9.31 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.70 (t, 1H), 8.00 (d, 1H), 7.80 (s, 1H), 7.60 (d, 1 H), 4.60 (s, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 1.90 (s, 3H). MS m/e 453 (M+Na), 431 (M+H).
  • Compound 3o is characterized as a yellow amorphous solid; R t 9.38 min; 1 H-NMR (DMSO-d 6 ) 67 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.00 (d, 1H), 7.80 (s, 1H), 7.60 (d, 1H), 7.40 (broad, 1H), 6.70 (broad, 1H), 4.50 (s, 2H), 3.25 (2 sets of t, 4H), 3.10 (q, 2H), 2.25 (broad m, 2H), 1.00 (t, 3H). MS m/e 482 (M+Na), 460 (M+H),
  • Compound 3p is characterized as a yellow amorphous solid; R t 11.73 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.10 (d, 1H), 8.00 (s, 1H), 7.60 (d, 1H), 5.00 (s, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 1.30 (s, 9H). MS m/e 516 (M+Na), 494 (M+H).
  • Compound 3r is characterized as a yellow amorphous solid; R t 11.25 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.70 (t, 1H), 8.00 (d, 1H), 7.70 (s, 1H), 7.50 (d, 1H), 4.60 (d, 2H), 3.25 (2 sets of t, 4H), 2.20 (m, 3H), 2.00 (broad, 2H), 0.90 (d, 6H). MS m/e 495 (M+Na), 473 (M+H).
  • Compound 3s is characterized as a yellow amorphous solid; R t 9.97 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.70 (t, 1H), 8.00 (d, 1H), 7.70 (s, 1H), 7.50 (d, 1H), 4.60 (d, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 4H), 1.00 (d, 3H). MS m/e 467 (M+Na), 445 (M+H).
  • Compound 3t is characterized as a yellow amorphous solid; R t 10.52 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.70 (broad t, 1H), 8.00 (d, 1H), 7.70 (s, 1H), 7.50 (d, 1H), 4.60 (d, 2H), 3.25 (2 sets of t, 4H), 3.00 (m, 1H), 2.25 (broad m, 2H), 1.00 (d, 6H). MS m/e 481 (M+Na), 458 (M+H).
  • Compound 3u is characterized as a yellow amorphous solid; R t 10.64 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.70 (broad t, 1H), 8.00 (d, 1H), 7.70 (s, 1H), 7.50 (d, 1H), 4.60 (d, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 2.10 (t, 2H), 1.50 (m, 2H), 0.70 (t, 3H). MS m/e 481 (M+Na), 458 (M+H).
  • Compound 3v is characterized as a yellow amorphous solid; R t 11.40 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.70 (t, 1H), 8.00 (d, 1H), 7.70 (s, 1H), 7.50 (d, 1H), 4.60 (d, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 2.10 (t, 2H), 1.50 (m, 2H), 1.20 (m, 2H), 0.70 (t, 3H). MS m/e 495 (M+Na), 473 (M+H).
  • Compound 3w is characterized as a yellow amorphous solid; R t 10.34 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 9.00 (broad t, 1H), 8.00 (d, 1H), 7.75 (s, 1H), 7.60 (d, 1H), 4.60 (d, 2H), 3.25 (m, 4H), 2.25 (broad m, 2H), 1.60 (m, 1H), 0.70 (broad, 4H). MS m/e 479 (M+Na), 457 (M+H).
  • Compound 3y is characterized as a yellow amorphous solid; R t 15.67 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.30 (s, 1H), 8.10 (d, 1H), 7.90 (s, 1H), 7.60 (d, 1H), 5.50 (s, 2H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H), 1.20 (s, 9H). MS m/e 472 (M ⁇ H).
  • Compound 3z is characterized as a yellow amorphous solid; R t 11.24 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.10 (d, 1H), 8.00 (s, 1H), 7.60 (d, 1H), 5.20 (s, 2H), 3.60 (s, 3H), 3.25 (2 sets of t, 4H), 2.25 (broad m, 2H). MS m/e 450 (M ⁇ H).
  • Compound 3aa is characterized as a yellow amorphous solid; R t 13.77 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.80 (s, 1H), 8.20 (s, 1H), 8.10 (d, 1H), 7.60 (d, 1H), 7.20 (s, 1H), 3.25 (2 sets of broad, 4H), 2.25 (broad m, 2H). MS m/e 425 (M ⁇ H).
  • Compound 4a is characterized as a yellow amorphous solid; R t 8.82 min (broad); 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.10 (d, 1H), 7.50 (d, 1H), 4.30 (d, 1H), 4.10 (d, 1H), 3.60 (m, 1H), 3.50 (s, 3H), 3.25 (2 sets of t, 4H), 2.70 (q, 1H), 2.25 (broad m, 2H), 2.10 (m, 1H), 1.70 (m, 4H); MS m/e 446 (M+H).
  • Compound 4b is characterized as a yellow amorphous solid; R t 9.73 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.50 (s, 1H), 8.20 (d, 1H), 7.60 (d, 1H), 4.20 (dd, 2H), 3.50 (m, 1H), 3.30 (m, 1H), 3.25 (2 sets of t, 4H), 3.00 (m, 1H), 2.80 (m, 1H), 2.25 (broad m, 2H), 2.00 (m, 1H), 1.80 (m, 2H), 1.30 (s, 9H). MS m/e 488 (M+H).
  • Compound 4c is characterized as a yellow amorphous solid; R t 6.64 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.20 (d, 1H), 7.60 (d, 1H), 4.80 (dd, 2H), 4.20 (broad, 1H), 3.50 (broad, 1H), 3.40-2.80 (m, 6H), 2.25 (broad m, 2H) 2.00 (m, 4H). MS m/e 432 (M+H).
  • Compound 4d is characterized as a yellow amorphous solid; R t 11.19 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.10 (d, 1H), 8.00 (broad, 1H), 7.50 (d, 1H), 6.70 (broad, 1H), 3.40-2.70 (a series of m, 8H), 2.50 (m, 4H), 2.25 (broad m, 2H), 1.20 (s, 9H). MS m/e 517 (M ⁇ H).
  • Compound 4e is characterized as a yellow amorphous solid; R t 7.23 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.30 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.10 (d, 1H), 8.20 (broad t, 1H), 8.00 (broad, 3H), 7.60 (d, 1H), 3.40-2.50 (a series of m, 12H), 2.25 (broad m, 2H). MS m/e 417 (M ⁇ H).
  • Compound 4j is characterized as a yellow amorphous solid; R t 7.99 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, 1H), 11.00 (s, 1H), 9.40 (s, 1H), 8.10 (d, 1H), 7.50 (d, 1H), 4.60 and 4.20 (2 sets of rotameric m, 1H), 3.70-1.70 (a series of m, 16H). MS m/e 472 (M ⁇ H).
  • Compound 4l is characterized as a yellow amorphous solid; R t 8.03 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, 1H), 10.90 (s, 1H), 10.80 (s, 1H), 9.10 (s, 1H), 8.00 (d, 1H), 7.50 (d, 1H), 3.40-3.25 (3 sets of t, 6H), 2.50 (t, 2H), 2.25 (broad m, 2H). MS m/e 371 (M ⁇ H).

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
US11/455,356 2000-05-09 2006-06-19 Novel multicyclic compounds and the use thereof Abandoned US20060276497A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
US11/455,356 US20060276497A1 (en) 2000-05-09 2006-06-19 Novel multicyclic compounds and the use thereof
ES07809679T ES2416309T3 (es) 2006-06-19 2007-06-19 Novedosos compuestos multicíclicos y el uso de los mismos
AU2007261464A AU2007261464B2 (en) 2006-06-19 2007-06-19 Novel multicyclic compounds and the use thereof
EP07809679.9A EP2066324B1 (en) 2006-06-19 2007-06-19 Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
DK07809679.9T DK2066324T3 (da) 2006-06-19 2007-06-19 Cycloalkanpyrrolocarbazolderivater og anvendelse deraf som parp, vegfr2 og mlk3 inhibitorer
PCT/US2007/014300 WO2007149451A2 (en) 2006-06-19 2007-06-19 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
PT78096799T PT2066324E (pt) 2006-06-19 2007-06-19 Derivados de cicloalcanopirrolocarbazole e sua utilização como inibidor de parp, vegfr2 e mlk3
NZ573643A NZ573643A (en) 2006-06-19 2007-06-19 CYCLOALKANOPYRROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS which are useful in the treatment of neurodegenerative diseases
PL07809679T PL2066324T3 (pl) 2006-06-19 2007-06-19 Pochodne cykloalkanopirolokarbazoli i ich zastosowanie jako inhibitory PARP, VEGFR2 i MLK3
MX2008016348A MX2008016348A (es) 2006-06-19 2007-06-19 Compuestos multiciclicos novedosos y el uso de los mismos.
JP2009516545A JP5385133B2 (ja) 2006-06-19 2007-06-19 新規多環式化合物およびその使用
CN200780029096.2A CN101500563B (zh) 2006-06-19 2007-06-19 环烷酰吡咯并咔唑衍生物及其作为parp、vegfr2和mlk3抑制剂的应用
CA2655014A CA2655014C (en) 2006-06-19 2007-06-19 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
SI200731252T SI2066324T1 (sl) 2006-06-19 2007-06-19 Derivati cikloalkanopirolokarbazola in uporaba le-teh kot inhibitorjev parp, vegfr2 in mlk3
IL195821A IL195821A (en) 2006-06-19 2008-12-09 Derivatives 5 (6h), 7- Dioxo-6- (4-Methylphiprazine-1-Il) -11,10,9,8,7,5-Hexhydrocyclopent [g] phenyl / pyrido [b [pyrrolo [4,3- e] Andol, pharmaceutical preparations containing them and their use in the preparation of medicines
HK09109830.6A HK1131747A1 (en) 2006-06-19 2009-10-23 Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
US12/949,254 US8716493B2 (en) 2000-05-09 2010-11-18 Multicyclic compounds and the use thereof
CY20131100589T CY1114153T1 (el) 2006-06-19 2013-07-11 Παραγωγα κυκλοαλκανοπυρρολοκαρβαzολιου και η χρηση αυτων ως αναστολεις parp, vegfr2 και mlk3

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20294700P 2000-05-09 2000-05-09
US09/850,858 US7122679B2 (en) 2000-05-09 2001-05-08 Multicyclic compounds and the use thereof
US11/455,356 US20060276497A1 (en) 2000-05-09 2006-06-19 Novel multicyclic compounds and the use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/850,858 Continuation-In-Part US7122679B2 (en) 2000-05-09 2001-05-08 Multicyclic compounds and the use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/949,254 Continuation US8716493B2 (en) 2000-05-09 2010-11-18 Multicyclic compounds and the use thereof

Publications (1)

Publication Number Publication Date
US20060276497A1 true US20060276497A1 (en) 2006-12-07

Family

ID=38695490

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/455,356 Abandoned US20060276497A1 (en) 2000-05-09 2006-06-19 Novel multicyclic compounds and the use thereof
US12/949,254 Expired - Fee Related US8716493B2 (en) 2000-05-09 2010-11-18 Multicyclic compounds and the use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/949,254 Expired - Fee Related US8716493B2 (en) 2000-05-09 2010-11-18 Multicyclic compounds and the use thereof

Country Status (17)

Country Link
US (2) US20060276497A1 (es)
EP (1) EP2066324B1 (es)
JP (1) JP5385133B2 (es)
CN (1) CN101500563B (es)
AU (1) AU2007261464B2 (es)
CA (1) CA2655014C (es)
CY (1) CY1114153T1 (es)
DK (1) DK2066324T3 (es)
ES (1) ES2416309T3 (es)
HK (1) HK1131747A1 (es)
IL (1) IL195821A (es)
MX (1) MX2008016348A (es)
NZ (1) NZ573643A (es)
PL (1) PL2066324T3 (es)
PT (1) PT2066324E (es)
SI (1) SI2066324T1 (es)
WO (1) WO2007149451A2 (es)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
US20100215665A1 (en) * 2007-06-08 2010-08-26 University Of Massachusetts Mixed lineage kinases and metabolic disorders
WO2011028580A1 (en) 2009-08-26 2011-03-10 Cephalon, Inc. Novel forms of a multicyclic compound
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
KR101514320B1 (ko) 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
WO2015121876A1 (en) 2014-02-14 2015-08-20 Council Of Scientific & Industrial Research Novel tricyclic compounds and preparation thereof
US9260459B2 (en) 2012-06-25 2016-02-16 Kyowa Hakko Kirin Co., Ltd. 4,6-hexadecadiene-2,4-dicarboxylic acid derivative
US9771325B2 (en) 2014-02-14 2017-09-26 Council Of Scientific & Industrial Research Tricyclic compounds and preparation thereof
WO2024026129A3 (en) * 2022-07-29 2024-03-07 Ensem Therapeutics, Inc. Tricyclic aryl derivatives, and compositions and methods thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192121A1 (en) * 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
MX2017006679A (es) * 2014-11-26 2018-07-06 Cephalon Inc Formas cristalinas de inhibidores de poli adp-ribosa polimerasa (parp).
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN107619386B (zh) * 2017-08-26 2020-10-13 湘潭大学 一种芳环并[c]咔唑类衍生物及其合成方法
US20190280143A1 (en) 2018-03-12 2019-09-12 Solar Junction Corporation Chirped distributed bragg reflectors for photovoltaic cells and other light absorption devices
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CN110028439B (zh) * 2019-04-25 2020-11-13 四川大学 邻苯二甲酰亚胺类衍生物及其制备方法和用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912107A (en) * 1988-09-29 1990-03-27 Goedecke Aktiengesellschaft Pyrrolocarbazole derivatives, compositions containing them, and methods for using them
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US6291447B1 (en) * 1998-03-13 2001-09-18 The University Of British Columbia Granulatimide compounds and uses thereof
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166204A (en) * 1989-11-01 1992-11-24 Toyama Chemical Co., Ltd. Isoindole derivatives and salts thereof and antitumor agent comprising the same
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
ATE246686T1 (de) 1995-03-09 2003-08-15 Kyowa Hakko Kogyo Kk Pyrrolocarbazolderivate
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
ATE230414T1 (de) 1998-02-12 2003-01-15 Molecumetics Ltd Mimetika von beta-faltblatt und verfahren zur verwendung davon
US6063803A (en) 1998-06-16 2000-05-16 Ortho-Mcneil Pharmaceutical, Inc. Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
JP4230385B2 (ja) 2004-03-05 2009-02-25 本田技研工業株式会社 追従走行制御装置

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4912107A (en) * 1988-09-29 1990-03-27 Goedecke Aktiengesellschaft Pyrrolocarbazole derivatives, compositions containing them, and methods for using them
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
USRE36397E (en) * 1994-02-04 1999-11-16 The John Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US6291447B1 (en) * 1998-03-13 2001-09-18 The University Of British Columbia Granulatimide compounds and uses thereof
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
US20080146556A1 (en) * 2006-11-20 2008-06-19 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
US20100215665A1 (en) * 2007-06-08 2010-08-26 University Of Massachusetts Mixed lineage kinases and metabolic disorders
US9061009B2 (en) 2007-06-08 2015-06-23 University Of Massachusetts Mixed lineage kinases and metabolic disorders
WO2011028580A1 (en) 2009-08-26 2011-03-10 Cephalon, Inc. Novel forms of a multicyclic compound
JP2016014029A (ja) * 2009-08-26 2016-01-28 セファロン、インク． 多環系化合物の新規形態
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
US9260459B2 (en) 2012-06-25 2016-02-16 Kyowa Hakko Kirin Co., Ltd. 4,6-hexadecadiene-2,4-dicarboxylic acid derivative
KR101514320B1 (ko) 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
WO2015121876A1 (en) 2014-02-14 2015-08-20 Council Of Scientific & Industrial Research Novel tricyclic compounds and preparation thereof
US9771325B2 (en) 2014-02-14 2017-09-26 Council Of Scientific & Industrial Research Tricyclic compounds and preparation thereof
WO2024026129A3 (en) * 2022-07-29 2024-03-07 Ensem Therapeutics, Inc. Tricyclic aryl derivatives, and compositions and methods thereof

Also Published As

Publication number Publication date
SI2066324T1 (sl) 2013-07-31
CA2655014A1 (en) 2007-12-27
IL195821A (en) 2016-05-31
AU2007261464A1 (en) 2007-12-27
JP2009541322A (ja) 2009-11-26
EP2066324B1 (en) 2013-05-29
WO2007149451B1 (en) 2008-04-10
PT2066324E (pt) 2013-08-01
IL195821A0 (en) 2009-09-01
WO2007149451A2 (en) 2007-12-27
CN101500563B (zh) 2015-05-06
EP2066324A2 (en) 2009-06-10
NZ573643A (en) 2012-01-12
PL2066324T3 (pl) 2013-10-31
CY1114153T1 (el) 2016-08-31
JP5385133B2 (ja) 2014-01-08
US8716493B2 (en) 2014-05-06
AU2007261464B2 (en) 2012-09-13
MX2008016348A (es) 2009-01-30
HK1131747A1 (en) 2010-02-05
DK2066324T3 (da) 2013-08-26
ES2416309T3 (es) 2013-07-31
CA2655014C (en) 2014-12-30
WO2007149451A3 (en) 2008-02-21
CN101500563A (zh) 2009-08-05
US20110059959A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
US8716493B2 (en) Multicyclic compounds and the use thereof
US7122679B2 (en) Multicyclic compounds and the use thereof
AU2007261305B2 (en) Fused (d)pyridazin-7-ones
AU2001261327B2 (en) Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
AU2001261327A1 (en) Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
ES2351268T3 (es) Compuestos multicíclicos y su uso como inhibidores de enzimas parp, vegfr2 y mlk3.

Legal Events

Date Code Title Description
AS Assignment

Owner name: CEPHALON, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHATTERJEE, SANKAR;DIEBOLD, JAMES L.;DUNN, DEREK;AND OTHERS;REEL/FRAME:018069/0534;SIGNING DATES FROM 20060721 TO 20060801

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE